Ceritinib

Evidence Level: L5

Predicted Indications: 9

Ceritinib

Pharmacist Assessment Report

Ceritinib: From Non-Small Cell Lung Cancer to fibromatosis, gingival

One-Sentence Summary

Ceritinib is an oral ALK/ROS1 kinase inhibitor, originally used to treat ALK-positive non-small cell lung cancer. The TxGNN model (deep learning) predicts it may be effective for gingival fibromatosis, but this is a model-based prediction only. There are 0 clinical trials and 0 publications supporting this specific indication, so the evidence is very weak.

Quick Overview

Item	Content
Original Indication	Non-small cell lung cancer (ALK-positive)
Predicted New Indication	Gingival fibromatosis
TxGNN Prediction Score	0.9986
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, ceritinib is a kinase inhibitor targeting ALK and ROS1, and its efficacy in ALK-rearranged non-small cell lung cancer has been established.

No mechanistic link has been identified between ALK/ROS1 inhibition and gingival fibromatosis, which is a benign overgrowth of gum tissue. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological or clinical evidence. The prediction should be treated as a hypothesis only.

Other predicted indications in the top 10 fall into three groups:

Lung tumours (lung hilum carcinoma, pulmonary sulcus neoplasm): these are likely subsets of the already approved NSCLC indication rather than true new uses.
Benign or rare lung and other tumours (fibroma of lung, hamartoma of lung, lung benign neoplasm, lung germ cell tumour): no direct evidence supports benefit.
Unrelated genetic disorders (e.g. junctional epidermolysis bullosa, VCP-related inclusion body myopathy): no known link to ALK inhibition.

Clinical Trial Evidence

Currently no related clinical trials registered for gingival fibromatosis.

Literature Evidence

Currently no related literature available for gingival fibromatosis.

For context, the literature retrieved for other predicted indications mainly covers ceritinib in its approved NSCLC use. This includes the ASCEND-4 phase 3 randomised trial (PMID 28126333, Lancet, 2017), which compared first-line ceritinib with platinum-based chemotherapy in ALK-rearranged NSCLC. It does not support the predicted new indication.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02436779	ZYKADIA	Not specified	Not specified

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (ALK/ROS1 tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert; literature flags QT prolongation, hypersensitivity/interstitial lung disease, and renal effects of ALK inhibitors as areas for monitoring
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions (100 interactions recorded; examples shown):

Major: triamcinolone, budesonide
Moderate: acid-suppressing drugs (famotidine, ranitidine, omeprazole, rabeprazole), other corticosteroids (dexamethasone, hydrocortisone, betamethasone), diabetes drugs (metformin, pioglitazone, alogliptin, acarbose, canagliflozin, albiglutide), aprepitant, loperamide, bisacodyl

A published study has specifically assessed the interaction between ceritinib and proton pump inhibitors (PMID 28424965).

Literature also flags QT prolongation with tyrosine kinase inhibitors including ceritinib, and a case of ceritinib hypersensitivity with diffuse infiltrative lung disease. Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no clinical trials or publications for gingival fibromatosis, and no plausible mechanistic link to ALK/ROS1 inhibition. Ceritinib also carries substantial safety and interaction burdens, which are hard to justify for a benign condition.

To proceed, the following is needed:

Mechanism of action data and a biological rationale connecting ALK/ROS1 signalling to gingival fibromatosis
Preclinical or case-level evidence in the proposed indication
Health Canada package insert warnings and contraindications
A benefit-risk assessment, given the safety profile in a benign condition
Evaluation of whether the lung-tumour predictions (hilum carcinoma, pulmonary sulcus neoplasm) are already covered by the approved NSCLC indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.